Hematologic Malignancy Research Program
Program Leader: Edward Stadtmauer, MD
For years, Penn's clinicians and researchers in hematologic malignancies have led the way nationally; both in the care of patients with blood cancers and in research on their causes, diagnosis, prognosis and treatment.
The success of the program relies on extensive collaboration with researchers and clinicians across specialties, including pathology and laboratory medicine, nuclear medicine, radiology and radiation oncology.
Over 100 scientists, clinicians, research nurses, technicians, and other research personnel are organized into three hematologic malignancies research programs:
Individualized treatment approaches are being investigated in all desease types that include the pathological analysis of tumor material in order to personalize medical treatments, including:
- Novel chemotherapeutic agents
- Targeted molecular and cellular therapy
- Therapeutic vaccine and monoclonal antibody and cellular immunologic therapy
These hold the promise for improved response and survival with decreased toxicity.
Both autologous and allogeneic bone marrow and stem cell transplantation approaches are utilized extensively for these diseases.
Medical oncologists involved in the management of hematologic malignancies include: